Literature DB >> 9306345

Validation of different methods to calculate Kt/V considering postdialysis rebound.

F Maduell1, J Garcia-Valdecasas, H Garcia, J Hernández-Jaras, F Sigüenza, C del Pozo, R Giner, R Moll, E Garrigos.   

Abstract

BACKGROUND: The effect of increasing dialysis efficiency magnifies rebound urea and the error in Kt/V determinations from single pool urea kinetics. Several formulae have been developed to calculate Kt/V taking into account the rebound urea (Kt/Vr). Smye et al. proposed a method whereby the equilibrated BUN is predicted by an additional intradialytic urea sample (Kt/VrSmye). Daugirdas et al. proposed a method where a single pool Kt/V is modified according to the speed of dialysis to obtain a double pool Kt/V (Kt/VrDaug). Maduell et al. developed a method based on analysis of post-dialysis urea rebound whereby the Kt/Vr is predicted according to the single pool Kt/V and K/V (Kt/VrMad). DESIGN OF THE STUDY: We compared Kt/Vr estimated by these three formulae (Smye, Daugirdas, and Maduell) in 384 patients consisting of 211 males and 173 females, who received dialysis according to their regular protocols. Plasma urea was measured at the beginning, 90-100 min following the start of dialysis, the end, and 45 min post-dialysis.
RESULTS: Post-dialysis rebound urea was 22.4 +/- 9.7%. Kt/V and Kt/Vr obtained with rea kinetic model Kt/V 1.184 +/- 0.22 and 0.984 +/- 0.20, respectively. These was a good correlation between Kt/Vr and the Smye formula (Kt/VrSmye = 0.956 +/- 0.21, r = 0.729, P < 0.001), and a better one for Daugirdas (Kt/VrDaug = 0.984 +/- 0.18, r = 0.931, P < 0.001), and Maduell formulae (Kt/VrMad = 0.980 +/- 0.18, r = 0.946, P < 0.001). Limits of agreement and percentage of error estimated according to Bland and Altman show that Kt/Vr estimated by Daugirdas and Maduell formulae could be used in place of the Kt/Vr. The degree of agreement with the Smye method is not clinically acceptable.
CONCLUSION: Our results suggest that the use of a single pool Kt/V is not adequate to estimate the haemodialysis dose delivered and Kt/V taking rebound urea in consideration. Kt/Vr estimated by Daugirdas or Maduell formulae are a simple and accurate method for use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306345     DOI: 10.1093/ndt/12.9.1928

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Body composition monitoring-derived urea distribution volume in children on chronic hemodialysis.

Authors:  Ariane Zaloszyc; Michel Fischbach; Betti Schaefer; Lorenz Uhlmann; Rémi Salomon; Saoussen Krid; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2016-01-11       Impact factor: 3.714

2.  Comparison of single-pool and equilibrated Kt/V values for pediatric hemodialysis prescription management: analysis from the Centers for Medicare & Medicaid Services Clinical Performance Measures Project.

Authors:  Stuart L Goldstein; Andrew Brem; Bradley A Warady; Barbara Fivush; Diane Frankenfield
Journal:  Pediatr Nephrol       Date:  2006-05-17       Impact factor: 3.714

3.  Randomized, double-blinded, controlled clinical trial of the effect of captopril, telmisartan and their combination on systemic inflammation of patients on hemodialysis.

Authors:  Susan M Ordaz-Medina; Alfonso M Cueto-Manzano; Juana González-Plascencia; José L Montañez-Fernández; Elias J Ordaz-Medina; Fabiola Martín-Del-Campo; Alfonso M Cueto-Ramírez; Petra Martínez-Martínez; Laura Cortés-Sanabria; Enrique Rojas-Campos; Benjamín Trujillo-Hernández
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

4.  Adequacy of dialysis in children: does small solute clearance really matter?

Authors:  Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

5.  Monitoring dialysis adequacy: history and current practice.

Authors:  Linda Ding; James Johnston; Maury N Pinsk
Journal:  Pediatr Nephrol       Date:  2021-01-05       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.